<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111954</url>
  </required_header>
  <id_info>
    <org_study_id>402/12</org_study_id>
    <nct_id>NCT02111954</nct_id>
  </id_info>
  <brief_title>Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients</brief_title>
  <official_title>PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lausanne Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new
      PET/CT radiotracer aiming at giving complementary information : more precise images and early
      localisation of recurrence to standard imaging
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will
      be proposed to participate to the present study. After signing the patient informed consent,
      both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval.

      No adverse events are expected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 28, 2016</completion_date>
  <primary_completion_date type="Actual">October 28, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positivity of the new radiotracer Ga-68-NODAGA-MJ9 compared to the standard radiotracer F-18-FCH</measure>
    <time_frame>At baseline (after F-18-FCH PET/CT)</time_frame>
    <description>PET images : SUVmax, SUVmean, VOI (mL), SUV41% lesions/ SUVbackground CT images : size lesions measured in 3D (axial, coronal and sagittal), density in Hounsfield Units (HU)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>F-18-FCH &amp; Ga-68-NODAGA-MJ9</arm_group_label>
    <description>1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9</intervention_name>
    <description>Each patient will have two PET/CT</description>
    <arm_group_label>F-18-FCH &amp; Ga-68-NODAGA-MJ9</arm_group_label>
    <other_name>1 PET/CT with F-18-FCH</other_name>
    <other_name>1 PET/CT with Ga-68-NODAGA-MJ9</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with proven prostate cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : adult patients

          -  Karnofsky : â‰¥ 80%

          -  Patients with histologically proven prostate cancer for whom 18F-fluocholine PET/CT is
             indicated for primary cancer staging, or for recurrence with increase of blood PSA. In
             order to provide a detection probability of 30% or more, a blood PSA 0.5 ng / ml or
             more in post initial curative intent surgery will be required.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Lack of discernment to sign the consent form

          -  Age &lt;18 years

          -  Patient under hormonal treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John O. Prior, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lausanne Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2014</study_first_submitted>
  <study_first_submitted_qc>April 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>May 20, 2017</last_update_submitted>
  <last_update_submitted_qc>May 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne Hospitals</investigator_affiliation>
    <investigator_full_name>John O. Prior</investigator_full_name>
    <investigator_title>Nuclear Medicine Department</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>primary</keyword>
  <keyword>recurrence</keyword>
  <keyword>F-18-FCH PET/CT</keyword>
  <keyword>Ga-68-NODAGA-MJ9 PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

